Celerion signs up to VCT's verified patient database project
VCT’s approach is to develop a database of subjects currently taking part in clinical trials that member organisations – such as Celerion – can access to ensure that a prospective subject is not already part of another clinical programme.
VCT and Celerion claim that modern recruitment techniques, coupled with economic pressures has seen an increase in the number of cash-strapped participants joining more than one study, seriously jeopardize the results of these trials.
Early stage clinical research solutions provider Celerion is one of the first organisations to have had its patients “verified” through the scheme.
Mitchell Efros, president and CEO of VCT, said: “Celerion has the largest Phase I bed capacity globally and sets the standard to protect their research participants and enhance data integrity.”
He added that VCT now hopes almost all of the most recognized CROs will be using the system by the end of 2012, saying the company wants to “ensure that only qualified participants proceed into screening, thereby saving the sponsor and sites time and money”.
Phil Bach, VP of global clinical research at Celerion said: “This implementation sets a standard in the industry to continue to improve clinical research and bring new drugs to the market place.”
Of VCT’s efforts to standardise recruitment, Bach added: “It is great news for the entire clinical research community that Verified Clinical Trials is boosting its presence and will have major affiliates in so many locations.
“The implementation of the Verified Clinical Trials solution at Celerion supports our commitment to apply rigorous standards to protect the safety of participants and enhance data integrity for sponsors.”
